1. Home
  2. THAR vs NBY Comparison

THAR vs NBY Comparison

Compare THAR & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • NBY
  • Stock Information
  • Founded
  • THAR 2017
  • NBY 2000
  • Country
  • THAR United States
  • NBY United States
  • Employees
  • THAR N/A
  • NBY N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • NBY
  • Sector
  • THAR Health Care
  • NBY
  • Exchange
  • THAR Nasdaq
  • NBY Nasdaq
  • Market Cap
  • THAR 3.3M
  • NBY 3.4M
  • IPO Year
  • THAR 2022
  • NBY 2007
  • Fundamental
  • Price
  • THAR $1.51
  • NBY $0.58
  • Analyst Decision
  • THAR Strong Buy
  • NBY Strong Buy
  • Analyst Count
  • THAR 1
  • NBY 1
  • Target Price
  • THAR $17.00
  • NBY $0.85
  • AVG Volume (30 Days)
  • THAR 26.3K
  • NBY 41.7K
  • Earning Date
  • THAR 05-12-2025
  • NBY 05-15-2025
  • Dividend Yield
  • THAR N/A
  • NBY N/A
  • EPS Growth
  • THAR N/A
  • NBY N/A
  • EPS
  • THAR N/A
  • NBY 0.57
  • Revenue
  • THAR N/A
  • NBY $9,781,000.00
  • Revenue This Year
  • THAR N/A
  • NBY $23.91
  • Revenue Next Year
  • THAR N/A
  • NBY $32.05
  • P/E Ratio
  • THAR N/A
  • NBY $1.27
  • Revenue Growth
  • THAR N/A
  • NBY 20.52
  • 52 Week Low
  • THAR $0.95
  • NBY $0.36
  • 52 Week High
  • THAR $6.39
  • NBY $3.15
  • Technical
  • Relative Strength Index (RSI)
  • THAR 54.61
  • NBY 52.01
  • Support Level
  • THAR $1.41
  • NBY $0.55
  • Resistance Level
  • THAR $1.64
  • NBY $0.61
  • Average True Range (ATR)
  • THAR 0.11
  • NBY 0.02
  • MACD
  • THAR 0.01
  • NBY 0.00
  • Stochastic Oscillator
  • THAR 63.86
  • NBY 50.00

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Share on Social Networks: